← Back to Search

Antioxidant

MitoQ for COPD

Phase < 1
Recruiting
Led By Paula Rodriguez-Miguelez, PhD
Research Sponsored by Virginia Commonwealth University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinically diagnosed of COPD
Global Initiative for obstructive lung disease (GOLD) Stages II to IV
Must not have
Raynaud's Phenomenon
Vasoactive medications
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 6 weeks

Summary

This trial tests if MitoQ, a mitochondrial-targeted antioxidant, can improve cardiovascular health in patients with COPD.

Who is the study for?
This trial is for adults with moderate to severe COPD (GOLD Stages II to IV). Participants must have a clinical diagnosis of COPD. They can't join if they have heart disease, are on vasoactive meds, have fluid in their lungs, gangrene, uncontrolled high blood pressure, Raynaud's Phenomenon, sleep apnea, a history of coagulation issues or diabetes.
What is being tested?
The study tests whether MitoQ—a mitochondrial-targeted antioxidant—can improve cardiovascular health in people with COPD. It compares the effects of MitoQ against a placebo (a substance with no therapeutic effect) to see if there's any benefit.
What are the potential side effects?
While specific side effects for MitoQ aren't listed here, antioxidants like it could potentially cause upset stomachs or allergic reactions. The exact side effects will be monitored and recorded throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with COPD.
Select...
My lung condition is moderate to very severe.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have Raynaud's Phenomenon.
Select...
I am not taking any medications for blood pressure or heart rate.
Select...
I have fluid in my lungs.
Select...
I have gangrene in my fingers or toes.
Select...
My high blood pressure is not under control.
Select...
I have diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Skeletal Muscle Oxygenation
Body Weight Changes
Body Weight Changes
Secondary study objectives
Change in arterial stiffness
Body Weight Changes

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MitoQExperimental Treatment1 Intervention
Participants will take 1 pill each day for 6 weeks
Group II: PlaceboPlacebo Group1 Intervention
Participants will take 1 pill each day for 6 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MitoQ
2006
Completed Phase 2
~250

Find a Location

Who is running the clinical trial?

Virginia Commonwealth UniversityLead Sponsor
719 Previous Clinical Trials
22,895,812 Total Patients Enrolled
American Heart AssociationOTHER
346 Previous Clinical Trials
4,971,153 Total Patients Enrolled
Paula Rodriguez-Miguelez, PhDPrincipal InvestigatorVirginia Commonwealth University

Media Library

MitoQ (Antioxidant) Clinical Trial Eligibility Overview. Trial Name: NCT05605548 — Phase < 1
Chronic Obstructive Pulmonary Disease Research Study Groups: MitoQ, Placebo
Chronic Obstructive Pulmonary Disease Clinical Trial 2023: MitoQ Highlights & Side Effects. Trial Name: NCT05605548 — Phase < 1
MitoQ (Antioxidant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05605548 — Phase < 1
~8 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top